{
    "root": "c6a3b6aa-e2be-48e9-a73d-07bb140b2f9d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rivaroxaban",
    "value": "20250320",
    "ingredients": [
        {
            "name": "Rivaroxaban",
            "code": "9NDF7JZ4M3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Hypromelloses",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "Cellulose, Microcrystalline",
            "code": "OP1R32D61U"
        },
        {
            "name": "Sodium Lauryl Sulfate",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "Polyethylene Glycol 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "rivaroxaban tablet factor xa inhibitor indicated : reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 )",
        "doid_entities": [
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "peripheral artery disease (DOID:0050830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050830"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75 100 mg ) daily ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivaroxaban tablets usp , 2.5 mg available packages listed : \u20222.5 mg tablets light yellow , round , biconvex film-coated tablets debossed \u201c 2.5 \u201d one side plain side free physical defects . tablets supplied packages listed : bottle containing 60 tablets ndc 43598-981-60 bottle containing 180 tablets ndc 43598-981-18 blister package containing 100 tablets ndc 43598-981-78 ( 10 blister cards containing 10 tablets ) store 20\u00bac 25\u00b0c ( 68\u00baf 77\u00b0f ) [ usp controlled room temperature ] . keep reach children .",
    "adverseReactions": "rivaroxaban tablets contraindicated patients : active pathological bleeding [ ( 5.2 ) ] severe hypersensitivity reaction rivaroxaban tablets ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "indications_original": "Rivaroxaban tablet is a factor Xa inhibitor indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) (1.7) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD (1.8)",
    "contraindications_original": "CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75 to 100 mg) once daily ( 2.1 )",
    "warningsAndPrecautions_original": "Rivaroxaban tablets USP, 2.5 mg available in the packages listed below:\u00a0\n                  \u20222.5 mg tablets are light yellow, round, biconvex film-coated tablets debossed with \u201c2.5\u201d on one side and plain on other side and free from physical defects. The tablets are supplied in the packages listed:\n                  Bottle containing 60 tablets NDC 43598-981-60 \n                  Bottle containing 180 tablets NDC 43598-981-18 \n                  Blister package containing 100 tablets NDC 43598-981-78\n                  (10 blister cards containing 10 tablets each) \n                  Store at 20\u00baC to 25\u00b0C (68\u00baF to 77\u00b0F) [see USP Controlled Room Temperature].\u00a0\n                  Keep out of the reach of children.",
    "adverseReactions_original": "Rivaroxaban tablets are contraindicated in patients with:\u00a0\n                  \n                     active pathological bleeding [see Warnings and Precautions (5.2)] \n                     severe hypersensitivity reaction to rivaroxaban tablets (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "Rivaroxaban",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        }
    ]
}